Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria: DSM-IV criteria for schizophrenia or schizoaffective disorder Current clozapine treatment Moderate illness severity and inadequate positive symptom response to clozapine treatment 6 month period of clozapine treatment with documented clozapine blood level greater than or equal to 350 ng/ml or clozapine and norclozapine blood level greater than or equal to 450 ng/ml Exclusion Criteria: Organic brain disorder Mental retardation Medical condition whose pathology or treatment could alter the presentation or treatment of schizophrenia or significantly increase the risk associated with the proposed treatment protocol Pregnancy DSM-IV criteria for current alcohol or substance dependence within the last 6 months or DSM-IV criteria for alcohol or substance abuse within the last month Previously received adjunctive risperidone (at doses greater than or equal to 8 mg/day) with their clozapine treatment for greater than or equal to 6 weeks
Sites / Locations
- Maryland Psychiatric Research Center
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Active
Placebo
Participants assigned to risperidone
Participants assigned to placebo